---
title: "KEYMED BIO has been included in the National Basic Medical Insurance Drug List"
description: "KEYMED BIO announced that its independently developed new drug Kangyueda® (SIPUQIBAI monoclonal antibody injection) has been included in the \"National Basic Medical Insurance, Maternity Insurance and "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/268847508.md"
published_at: "2025-12-07T05:00:21.000Z"
---

# KEYMED BIO has been included in the National Basic Medical Insurance Drug List

> KEYMED BIO announced that its independently developed new drug Kangyueda® (SIPUQIBAI monoclonal antibody injection) has been included in the "National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalog (2025)," which will be officially implemented on January 1, 2026

On December 7th, KEYMED BIO announced that its independently developed national Class 1 new drug Kangyueda® (Siponimod Injection) has been included in the "National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalog (2025)," which will be officially implemented starting January 1, 2026

### Related Stocks

- [02162.HK - KEYMED BIO-B](https://longbridge.com/en/quote/02162.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Medicare Advantage's once-blistering growth dropped in 2026. Here's what that means. | Medicare Advantage's growth has slowed in 2026, with 35.5 million enrollees, a 3.2% increase from 2025, down from previo | [Link](https://longbridge.com/en/news/276521353.md) |
| Bpcl gets tax demand order worth 18.17 billion rupees | Bpcl gets tax demand order worth 18.17 billion rupees | [Link](https://longbridge.com/en/news/276594373.md) |
| FDA Dropping Requirement For 2 Studies For New Drug Approvals | The FDA has announced a significant change in its drug approval process, now allowing new drugs to be approved based on  | [Link](https://longbridge.com/en/news/276498156.md) |
| Novartis Presents Rhapsido®? (Remibrutinib) Data At Aaaai, Showing Potential Beyond Chronic Spontaneous Urticaria | Novartis will present data on Rhapsido® (remibrutinib), a selective oral BTK inhibitor, at the AAAAI Annual Meeting from | [Link](https://longbridge.com/en/news/276609493.md) |
| Ant Group’s Alipay AI Pay and AI Health App AQ Each Surpass 100 Million Users During CNY as AI Adoption Accelerates in China | Ant Group's Alipay AI Pay and AI Health App AQ each surpassed 100 million users during the 2026 Chinese New Year, reflec | [Link](https://longbridge.com/en/news/276585392.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.